KPI-121 + Vehicle
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharitis
Conditions
Blepharitis
Trial Timeline
Jul 1, 2014 → Jun 1, 2016
NCT ID
NCT02218489About KPI-121 + Vehicle
KPI-121 + Vehicle is a phase 2 stage product being developed by Kala Pharmaceuticals for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02218489. Target conditions include Blepharitis.
What happened to similar drugs?
5 of 10 similar drugs in Blepharitis were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02218489 | Phase 2 | Completed |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 37 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 34 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 32 |
| Lotilaner + Vehicle Control | LianBio | Phase 3 | 30 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 40 |
| ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone | Sun Pharmaceutical | Phase 3 | 40 |
| AzaSite® | Merck | Approved | 43 |
| AzaSite® | Merck | Approved | 43 |
| AzaSite® | Merck | Approved | 43 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 35 |
| AzaSite® | Merck | Approved | 43 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 35 |
| Azithromycin ophthalmic solution, 1% + Vehicle | Merck | Phase 2 | 27 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 29 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 39 |